UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037435
Receipt number R000042642
Scientific Title The evaluation of the absorption of lycopene derived from processed tomato extract compared to natural tomato extract -A Randomized, Double-blind, Placebo-controlled Crossover trial-
Date of disclosure of the study information 2020/07/17
Last modified on 2023/06/30 10:47:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The evaluation of the absorption of lycopene derived from processed tomato extract compared to natural tomato extract
-A Randomized, Double-blind, Placebo-controlled Crossover trial-

Acronym

The evaluation of the absorption of lycopene derived from processed tomato extract

Scientific Title

The evaluation of the absorption of lycopene derived from processed tomato extract compared to natural tomato extract
-A Randomized, Double-blind, Placebo-controlled Crossover trial-

Scientific Title:Acronym

The evaluation of the absorption of lycopene derived from processed tomato extract

Region

Japan


Condition

Condition

None(Healthy subjects)

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

A double-blind, placebo-controlled crossover trial will be conducted to evaluate blood kinetics of lycopene upon ingestion of foods containing processed tomato extract regarding the absorption of lycopene to serum.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Comparison of the serum lycopene concentration at each sampling point and AUC 0-12h of lycopene after intake of processed tomato extract with normal tomato extract(The analysis of actual measured values and the amount of changes values from baseline after the loading tomato extracts).

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

single ingestion of the natural extract - washout period(6 days or more)- single ingestion of the processed extract

Interventions/Control_2

single ingestion of the processed extract - washout period(6 days or more)- single ingestion of the natural extract

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

59 years-old >=

Gender

Male and Female

Key inclusion criteria

1)Japanese males and females from 20 to 59 years old when the consent is obtained
2)Healthy participants
3)Subjects who can be collected their blood multiple times(6 times per day)
4)Subjects with the normal fasting serum triglyceride value and LDL-cholesterol value

Key exclusion criteria

1)Subjects who are pregnant.
2)Smokers.
3)Subjects with a history of cancers or gastrointestinal diseases (except appendicitis).
4)Subjects who take the medicine related to lipids absorption.
5)Subjects who take the same medicine habitually.
6)Subjects with diseases such as autoimmune diseases, chronic inflammatory diseases and the diabetes mellitus.
7)Subjects who take the excessive alcohol(equivalent alcohol to 633 mL of beer or more at least 5 days a week).
8)Subjects who participate in another clinical trial.
9)Subjects with serious anemia.
10)Subjects who donated 200 mL or 400 mL whole blood or were transfused within 3 months before the screening.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Takashi
Middle name
Last name Koikeda

Organization

Shiba Palace Clinic

Division name

Chair

Zip code

105-0013

Address

6F DaiwaA Hamamatucho Bld., 1-9-10 Hamamatsucho, Minato-ku, Tokyo, 105-0013, Japa

TEL

03-5408-1599

Email

jimukyoku@mail.souken-r.com


Public contact

Name of contact person

1st name Yoshiyuki
Middle name
Last name Shirakura

Organization

FUJIFILM Healthcare Laboratory Co., Ltd.

Division name

Department of Supplement product management

Zip code

206-0024

Address

6F Kenkyu Bld., 2-5-1, Suwa, Tama-shi, Tokyo

TEL

042-339-8926

Homepage URL


Email

yoshiyuki.shirakura@fujifilm.com


Sponsor or person

Institute

Shiba Palace Clinic

Institute

Department

Personal name



Funding Source

Organization

FUJIFILM Corporation

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Shiba Palace Clinic

Address

6F DaiwaA Hamamatsucho Bld., 1-9-10 Hamamatsucho, Minato-ku, Tokyo, 105-0013, Japan

Tel

03-5408-1590

Email

jimukyoku@mail.souken-r.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 07 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 07 Month 03 Day

Date of IRB

2019 Year 06 Month 27 Day

Anticipated trial start date

2019 Year 07 Month 22 Day

Last follow-up date

2020 Year 07 Month 18 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 07 Month 20 Day

Last modified on

2023 Year 06 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042642


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name